1 情形 药品名称 中国境内 1 商品名 中国境内 1 首次获批上市时间 2025 年国家医保目录 新纳入 芦沃美替尼片 复迈宁 2025 年 5 月 枸橼酸伏维西利胶囊 复妥宁 2025 年 5 月 吡仑帕奈口服混悬液 奥捷宁 2025 年 9 月 盐酸替那帕诺片 万缇乐 2025 年 2 月 普托马尼片 普瑞尼 2024 年 12 月 备注信息调整 （新增适应症） 盐酸凯普拉生片 倍稳 2023 年 2 月 备注信息调整 （适应症表述更新） 拓培非格司亭注射液 珮金 2023 年 6 月 商保创新药目录 新纳入 阿基仑赛注射液 奕凯达 2021 年 6 月 一、新获纳入或涉及备注信息调整的主要品种 二、对上市公司的影响及风险提示 2025 年国家医保目录、商保创新药目录将于 2026 年 1 月 1 日起执行。其中， 2025 年国家医保目录的具体医保支付标准、医保报销细则、谈判药品的协议有 效期等信息，须以国家医疗保障局等相关政府部门公示信息为准。 证券代码：600196 股票简称：复星医药 编号：临 2025-192 上海复星医药（集团）股份有限公司 关于公司药品新纳入国家医保目录 及商保创新药目录的 ...

复星医药公告称，根据2025年12月7日发布的2025年国家医保目录和商保创新药目录，集团多款已上市 产品获首次纳入或涉及备注信息调整，如芦沃美替尼片、阿基仑赛注射液等。两目录将于2026年1月1日 起执行。相关药品2024年度及2025年前三季度销售额合计分别约为4.01亿元、8.92亿元，分别占同期集 团营收的0.98%、3.04%。本次纳入预计对集团后续业绩产生积极影响，但具体影响尚无法确定。 ...

12月3日，据CDE官网显示，复星医药控股子公司复宏汉霖提交的3.3类 地舒单抗注射液（HLX14）生物类似药的上市注册申请已获受理，主要用于治疗绝 经后妇女骨质疏松症、男性骨质疏松症及糖皮质激素诱导的骨质疏松症。该产品在欧美英三地相继获批后，此次国内申报是其关键进展，为国内患者提供了 | | 受庫号 | 药品名称 | 药品类型 | 申请类型 | 注册分类 | 企业名称 | 承办日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | | CXSS2500128 | 地舒单抗注射液 | 治疗用生 物制品 | 新药 | 3.3 | 复星汉霖(深圳)生物 技术有限公司;上海复宏 汉霖生物医药有限公司; | 2025-12-03 | | | CXSS2500127 | 地舒单抗注射液 | 治疗用生 | 新药 | 3.3 | 复星汉索(深圳)生物 技术有限公司;上海复宏 | 2025-12-03 | | 文件择 | | | 物制品 | | | 汉霖生物医药有限公司; | 日常程度 | 新的治疗选择。 截图来源：CDE官网 地舒单抗类似药竞争"升温"，复星医药超2 ...

近日，复星健康与Fakeeh Care Group在沙特吉达正式签署战略合作备忘录。双方围绕专科建设与学术交流、IT与数字化医院解决方案、预防医学与可穿戴设 备、干细胞与再生医学四大核心方向达成战略合作探索意向，为"一带一路"倡议下中沙医疗健康合作注入新活力，也为沙特"2030 愿景"医疗板块升级添砖 加瓦。 近日，复星健康董事长兼首席执行官胡航，复星健康联席总裁、首席战略官沈赟，复星健康副总裁、佛山复星禅诚医院院长赵晓东等领导团队，受邀前往沙 特阿拉伯，对当地领先的私营医疗健康集团Fakeeh Care Group进行实地考察与深度交流。 复星健康领导一行参观了该集团位于吉达的旗舰医院，双方围绕医院规划、学科运营和服务质量等议题展开深入探讨。复星健康董事长兼首席执行官胡航对 Fakeeh Care Group医院体系化的管理、先进设施和高标准服务表示赞赏，期待双方团队紧密协作，推动合作项目扎实落地。Fakeeh Care Group吉达旗舰医院 首席执行官Sohail Bajammal博士表示，沙特医疗市场需求广阔，期待引入复星健康在中国市场的经验与创新模式，共同促进项目在沙成功实施。 随后，在复星健康董事 ...

证券代码：600196 证券简称：复星医药 公告编号：临2025-190 上海复星医药（集团）股份有限公司关于 2025年A股股票期权激励计划首次授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性、完整性承担法律责任。 重要内容提示： ●A股期权首次授予登记日：2025年12月2日 ●A股期权首次授予登记数量：4,446,400份 根据《上海复星医药（集团）股份有限公司2025年A股股票期权激励计划》（以下简称"2025年A股期权 计划"或"本次激励计划"）及上海复星医药（集团）股份有限公司（以下简称"本公司"）2025年第一次 临时股东会的授权，本次激励计划首次授予及登记工作已完成，现将相关事项公告如下： 一、本次激励计划首次授予情况 2025年11月4日，本公司第十届董事会第十四次会议审议通过关于2025年A股期权计划首次授予相关事 项的议案，董事会认为本次激励计划首次授予的条件已经成就，同意以2025年11月4日作为首次授予 日、向共计195名首次授予激励对象授予合计4,535,100份A股期权，并办理该授予所需的相关事宜。该 议案 ...

证券日报网讯12月3日晚间，复星医药（600196）发布公告称，近日，上海复星医药(集团)股份有限公 司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS887片(项目代号及 以下简称"FXS0887")用于晚期恶性实体瘤开展临床试验的批准。复星医药产业拟于条件具备后于中国 境内开展FXS0887的I期临床试验。 ...

Group 1 - Dongfang Electric announced that three executives plan to reduce their holdings by a total of no more than 30,000 shares due to personal financial needs [1] - Yahu Pharmaceutical's APL-1401 clinical trial data was presented at the 19th European Colorectal Congress, indicating progress in treating moderate to severe ulcerative colitis [1] - Guizhou Bai Ling's actual controller is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [3] Group 2 - Bairen Medical's ePTFE pericardial membrane product has been approved for registration, ending the reliance on imports for this product in the domestic market [4] - Qianxin received approval for a total of 2 billion yuan in technology innovation bonds, with plans to issue medium-term notes and short-term financing bonds [6] - Tengjing Technology's shareholder plans to reduce holdings by no more than 1.96% of the company's shares [7] Group 3 - Yuntianhua's subsidiary is required to pay 386 million yuan in overdue taxes and penalties, which will impact the company's net profit for 2025 [8] - Jianyou Pharmaceutical's propofol emulsion injection has received FDA approval in the United States [9] - Suzhou Gaoxin successfully acquired land use rights for a residential project for 360 million yuan [9] Group 4 - Chalco International's subsidiary won a bid for a 3.03 billion yuan electrolytic aluminum project [11] - Tai Long Pharmaceutical's stock will continue to be suspended due to potential changes in control as the major shareholder is planning a share transfer [12] - Qianli Technology reported a 63.44% year-on-year increase in automobile sales for November, although new energy vehicle sales decreased by 43.98% [13] Group 5 - Fosun Pharma's innovative drug FXS0887 has received approval for a Phase I clinical trial for advanced malignant solid tumors [14] - Guoen Co. has obtained approval for a project to produce 20,000 square meters of aviation-grade acrylic glass, with a total investment of 560 million yuan [15] - Guofa Co.'s chairman resigned due to personal reasons [17] Group 6 - Shanghai Construction won a bid for a state-owned construction land use right for 264 million yuan [18] - Weixin Kang's subsidiary received approval for a clinical trial of lidocaine cream for local anesthesia [20] - Sanxing Medical's subsidiary is a candidate for a 152 million yuan transformer procurement project for the State Grid [20] Group 7 - People's Daily announced the resignation of its president due to work changes, while retaining other leadership roles [21] - Beibu Gulf Port reported a 0.29% year-on-year increase in cargo throughput for November [22] - Chongqing Construction won three engineering projects with a total value of approximately 2.773 billion yuan [23] Group 8 - Xingyu Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange [24] - Huajian Group signed a design contract worth 160 million yuan for a comprehensive project [25] - Wankai New Materials plans to invest 350 million yuan in a technical transformation project for producing 100,000 tons of adipic acid [26] Group 9 - Kaipuyun received a government subsidy of 18 million yuan, which is 87.43% of its net profit for the last audited fiscal year [28] - Ningbo Port expects a 10.8% year-on-year increase in container throughput for November [30] - An Cai High-Tech plans to invest 498 million yuan to upgrade its photovoltaic glass production line [32] Group 10 - Shunhao Co. stated that its existing business has not generated synergies with the rail business, which faces various risks [34] - Yihualu plans to publicly transfer 35% of its stake in Liaoyun Company [35] - ST Wanfang's shareholder plans to reduce holdings by no more than 3% of the company's shares [36] Group 11 - Youyou Food's shareholder plans to reduce holdings by no more than 110,000 shares [38] - Hengtong Optic-Electric's incentive fund has spent 49.98 million yuan to purchase company shares [41] - Zoli Pharmaceutical plans to issue convertible bonds to raise no more than 1.556 billion yuan for various projects [42]

截至2025年10月，集团现阶段针对FXS0887的累计研发投入约为人民币0.44亿元(未经审计)。截至本公 告日期(即2025年12月3日)，于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。 FXS0887 为集团(即公司及控股子公司/单位，下同)自主研发的口服小分子创新药物，拟用于治疗晚期 恶性实体瘤。FXS0887可特异性抑制ATR(Ataxia Telangiectasia and Rad3-related)激酶活性，通过干预细 胞周期调控和DNA损伤修复相关通路，从而抑制肿瘤细胞的恶性增殖。截至目前的临床前研究显示， FXS0887 在多种类型肿瘤模型中表现出良好的抗肿瘤活性，脱靶风险较小，安全性良好。 复星医药(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称"公司")控股子公司上海 复星医药产业发展有限公司(以下简称"复星医药产业")收到国家药品监督管理局关于同意FXS887片(项 目代号及以下简称"FXS0887")用于晚期恶性实体瘤开展临床试验的批准。复星医药产业拟于条件具备 后于中国境内1开展FXS0887的I期临床试验。 ...

复星医药（600196）(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称"公司")控股 子公司上海复星医药产业发展有限公司(以下简称"复星医药产业")收到国家药品监督管理局关于同意 FXS887片(项目代号及以下简称"FXS0887")用于晚期恶性实体瘤开展临床试验的批准。复星医药产业拟 于条件具备后于中国境内1开展FXS0887的I期临床试验。 截至2025年10月，集团现阶段针对FXS0887的累计研发投入约为人民币0.44亿元(未经审计)。截至本公 告日期(即2025年12月3日)，于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。 FXS0887为集团(即公司及控股子公司/单位，下同)自主研发的口服小分子创新药物，拟用于治疗晚期恶 性实体瘤。FXS0887可特异性抑制ATR(Ataxia Telangiectasia and Rad3-related)激酶活性，通过干预细胞 周期调控和DNA损伤修复相关通路，从而抑制肿瘤细胞的恶性增殖。截至目前的临床前研究显示， FXS0887在多种类型肿瘤模型中表现出良好的抗肿瘤活性，脱靶风险较小，安全性良好。 ...

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]